Lista de obras -

18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.

scientific article published on 04 March 2013

2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

scientific article published on 01 January 2019

944OBRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+ PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP

artículo científico publicado en 2014

A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score

artículo científico publicado en 2010

A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients

artículo científico publicado en 2009

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial

artículo científico publicado en 2015

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States

artículo científico publicado en 2016

A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.

artículo científico publicado en 2013

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

artículo científico publicado en 2013

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

artículo científico publicado en 2019

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma

artículo científico publicado en 2017

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States

artículo científico publicado en 2017

Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).

artículo científico publicado en 2015

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma

artículo científico publicado en 2019

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

artículo científico publicado en 2015

Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.

artículo científico publicado en 2011

Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry

article published in 2012

Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center

scientific article published on 06 December 2018

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

artículo científico publicado en 2016

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study

artículo científico publicado en 2014

Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma

scientific article published on 06 March 2020

Central nervous system involvement in T-cell lymphoma: A single center experience

scientific article published on 04 April 2016

Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma

artículo científico publicado en 2020

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

artículo científico publicado en 2015

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

artículo científico publicado en 2005

Clinical roundtable monograph. Current management and treatment of T-cell lymphoma: A multidisciplinary approach

artículo científico publicado el 1 de junio de 2010

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation

artículo científico publicado en 2019

Communication between oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis

artículo científico publicado en 2017

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma

artículo científico publicado en 2015

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

scientific article published on 05 October 2015

Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature

scientific article published on 21 November 2018

Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome

artículo científico publicado en 2014

Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: a single-center, retrospective study

artículo científico publicado en 2014

Diffuse Large B-Cell Lymphoma Version 1.2016

scientific article published on 01 February 2016

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

artículo científico publicado en 2017

Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

scientific article published on 20 October 2018

Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: a cluster randomized controlled trial

artículo científico publicado en 2018

Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population

artículo científico publicado en 2016

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

artículo científico publicado en 2017

Fear of cancer recurrence in lymphoma survivors: A descriptive study

artículo científico publicado en 2019

Five-Year Outcomes for Frontline Brentuximab Vedotin with CHP for CD30 Expressing Peripheral T-Cell Lymphomas

artículo científico publicado en 2018

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

artículo científico publicado en 2017

How I treat breast implant-associated anaplastic large cell lymphoma.

artículo científico publicado en 2018

How I treat the peripheral T-cell lymphomas

artículo científico publicado en 2014

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma ⬇️

artículo científico publicado el 6 de marzo de 2012

Immunotherapy in mycosis fungoides: opening night or dress rehearsal?

scientific article published on 11 January 2019

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

artículo científico publicado en 2018

Lenalidomide in Adult T-Cell Leukemia/Lymphoma

artículo científico publicado en 2016

Long-term follow-up and management of small and medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferations of acral sites: a multicenter experience

artículo científico publicado en 2016

Long‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis ⬇️

artículo científico publicado el 1 de octubre de 2012

Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides

artículo científico publicado en 2016

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

artículo científico publicado en 2018

Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face

artículo científico publicado en 2014

Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors

artículo científico publicado en 2014

Mycosis fungoides, Psoriasis and Anti-PD-1 - A New Aspect of Known Associations

artículo científico publicado en 2018

Mycosis fungoides, Psoriasis und PD-1-Inhibitoren - neuer Aspekt einer bekannten Assoziation

scientific article published on 01 February 2019

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

artículo científico publicado en 2010

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

artículo científico publicado en 2017

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

artículo científico publicado en 2016

Non-Hodgkin's Lymphomas, version 3.2012

artículo científico publicado en 2012

Non-Hodgkin's lymphomas

artículo científico publicado en 2008

Non-Hodgkin's lymphomas

artículo científico publicado en 2011

Non-Hodgkin's lymphomas, version 1.2013.

artículo científico publicado en 2013

Non-Hodgkin's lymphomas, version 2.2014

artículo científico publicado en 2014

Non-Hodgkin's lymphomas, version 4.2014.

artículo científico publicado en 2014

Novel Immunotherapies for T Cell Lymphoma and Leukemia

scientific article published on 01 December 2018

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

artículo científico publicado en 2014

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

artículo científico publicado en 2015

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network

artículo científico publicado en 2018

Peripheral T-cell lymphoma – are we making progress?

artículo científico publicado en 2018

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

artículo científico publicado en 2015

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

artículo científico publicado en 2015

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma

artículo científico publicado en 2012

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

artículo científico publicado en 2009

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma

scientific article published on 01 April 2018

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

artículo científico publicado en 2011

Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile

scientific article published on 12 June 2018

Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification

artículo científico publicado en 2013

Primary cutaneous B-cell lymphomas: part II. Therapy and future directions

artículo científico publicado en 2013

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers

artículo científico

Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab

artículo científico publicado en 2017

Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study

artículo científico publicado en 2011

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

artículo científico publicado en 2017

Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma

artículo científico publicado en 2015

Protocol for a cluster randomised trial of a communication skills intervention for physicians to facilitate survivorship transition in patients with lymphoma

artículo científico publicado en 2016

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma

artículo científico publicado en 2016

Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.

artículo científico publicado en 2017

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial

scientific article published on 13 February 2003

Role of Single Agent and Combination Chemotherapy Strategies in Relapsed/Refractory Peripheral T-Cell Lymphoma: Results from the Complete Registry

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

artículo científico publicado en 2016

Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses

artículo científico publicado en 2014

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma

artículo científico publicado en 2016

Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials

artículo científico

Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients

artículo científico publicado en 2018

Survivorship care planning after participation in communication skills training intervention for a consultation about lymphoma survivorship

artículo científico publicado en 2015

Symptomatic delayed seromas vs incidental findings on MR, and likelihood of BIA-ALCL in women with textured implants

Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma

artículo científico publicado en 2018

T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

artículo científico publicado en 2016

T-cell receptor-δ expression and γδ+ T-cell infiltrates in primary cutaneous γδ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders

artículo científico publicado en 2018

Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features

artículo científico publicado en 2020

Targeting histone deacetylases in T-cell lymphoma

artículo científico publicado en 2016

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

artículo científico publicado en 2017

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

artículo científico publicado en 2017

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

artículo científico publicado en 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

artículo científico publicado en 2016

The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?

artículo científico publicado en 2017

The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project.

artículo científico publicado en 2018

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

artículo científico publicado en 2014

Treatment of Rosai–Dorfman disease with oral bexarotene: a case series

artículo científico publicado en 2018

Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy

scientific article published on 04 May 2018

Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.

artículo científico publicado en 2015

mTOR inhibition in T-cell lymphoma: a path(way) forward.

artículo científico publicado en 2015

Lista de obras de

18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.

2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

944OBRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+ PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP

A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score

A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States

A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States

Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).

Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.

Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.

Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry

Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study

Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma

Central nervous system involvement in T-cell lymphoma: A single center experience

Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

Clinical roundtable monograph. Current management and treatment of T-cell lymphoma: A multidisciplinary approach

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation

Communication between oncologists and lymphoma survivors during follow-up consultations: A qualitative analysis

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature

Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome

Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: a single-center, retrospective study

Diffuse Large B-Cell Lymphoma Version 1.2016

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: a cluster randomized controlled trial

Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Fear of cancer recurrence in lymphoma survivors: A descriptive study

Five-Year Outcomes for Frontline Brentuximab Vedotin with CHP for CD30 Expressing Peripheral T-Cell Lymphomas

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium

How I treat breast implant-associated anaplastic large cell lymphoma.

How I treat the peripheral T-cell lymphomas

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma ⬇️

Immunotherapy in mycosis fungoides: opening night or dress rehearsal?

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Lenalidomide in Adult T-Cell Leukemia/Lymphoma

Long-term follow-up and management of small and medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferations of acral sites: a multicenter experience

Long‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis ⬇️

Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face

Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors

Mycosis fungoides, Psoriasis and Anti-PD-1 - A New Aspect of Known Associations

Mycosis fungoides, Psoriasis und PD-1-Inhibitoren - neuer Aspekt einer bekannten Assoziation

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

Non-Hodgkin's Lymphomas, version 3.2012

Non-Hodgkin's lymphomas

Non-Hodgkin's lymphomas

Non-Hodgkin's lymphomas, version 1.2013.

Non-Hodgkin's lymphomas, version 2.2014

Non-Hodgkin's lymphomas, version 4.2014.

Novel Immunotherapies for T Cell Lymphoma and Leukemia

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network

Peripheral T-cell lymphoma – are we making progress?

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile

Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification

Primary cutaneous B-cell lymphomas: part II. Therapy and future directions